Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E8.64 EPS (ttm)8.79 Insider Own0.30% Shs Outstand1.32B Perf Week3.82%
Market Cap99.87B Forward P/E11.08 EPS next Y6.85 Insider Trans-19.59% Shs Float1.30B Perf Month3.92%
Income11.60B PEG- EPS next Q1.69 Inst Own79.60% Short Float1.54% Perf Quarter-10.21%
Sales27.48B P/S3.63 EPS this Y-16.50% Inst Trans2.71% Short Ratio2.44 Perf Half Y16.47%
Book/sh19.02 P/B3.99 EPS next Y-21.26% ROA19.40% Target Price85.70 Perf Year4.37%
Cash/sh21.57 P/C3.52 EPS next 5Y-12.39% ROE53.40% 52W Range63.76 - 86.27 Perf YTD5.96%
Dividend2.08 P/FCF10.98 EPS past 5Y41.20% ROI31.00% 52W High-12.04% Beta1.15
Dividend %2.74% Quick Ratio3.60 Sales past 5Y29.40% Gross Margin84.80% 52W Low19.01% ATR1.46
Employees9000 Current Ratio3.70 Sales Q/Q-13.20% Oper. Margin57.80% RSI (14)57.02 Volatility2.08% 1.98%
OptionableYes Debt/Eq1.18 EPS Q/Q-17.10% Profit Margin42.20% Rel Volume1.12 Prev Close74.22
ShortableYes LT Debt/Eq1.11 EarningsJan 25 AMC Payout22.90% Avg Volume8.20M Price75.88
Recom2.40 SMA204.01% SMA50-0.88% SMA2004.86% Volume9,179,903 Change2.24%
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Dec-11-17 07:30PM  Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Business Wire
06:09PM  Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta Zacks
02:24PM  What's Causing Juno Therapeutics Shares to Tumble 11.9% Today Motley Fool
12:06PM  Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today Zacks
10:29AM  Company News For Dec 11, 2017 Zacks
10:09AM  Gilead Sciences: Better Data, Better Stock? Barrons.com
08:10AM  Todays Research Reports on Stocks to Watch: Gilead Sciences and Alexion Pharmaceuticals ACCESSWIRE
07:55AM  Republican tax bill makes big winners of Amgen, Gilead and other drugmakers MarketWatch
Dec-10-17 12:47PM  Republican tax bill makes big winners of Amgen, Gilead and other drugmakers MarketWatch
11:34AM  Is Gilead Sciences, Inc. a Buy? Motley Fool
10:30AM  Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma Business Wire
10:30AM  Gilead's new drug keeps 56 pct of lymphoma trial patients alive Reuters
Dec-08-17 12:55PM  ETFs with exposure to Gilead Sciences, Inc. : December 8, 2017 Capital Cube
10:48AM  Gilead Sciences: Look Who's Shopping! Barrons.com
09:57AM  Why Biotech Stocks May Wait A While Before Feeling The Love Investor's Business Daily
09:43AM  Gilead Sciences to Acquire Cell Design Labs for $567 Million Zacks
Dec-07-17 06:05PM  Gilead to buy Cell Design Labs for up to $567 mln Reuters
05:57PM  Gilead to pop up to $567 million on East Bay 'smart cell' startup American City Business Journals
05:33PM  Gilead Sciences to buy Cell Design Labs for $567 million MarketWatch
05:20PM  Gilead to buy Cell Design Labs for up to $567 million Reuters
05:00PM  Gilead Sciences to Acquire Cell Design Labs GlobeNewswire
05:00PM  Gilead Sciences and Kite to Acquire Cell Design Labs Business Wire
Dec-06-17 04:50PM  Top 5 Biotech Stocks for 2017 Investopedia
04:23PM  Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches Investor's Business Daily
10:13AM  Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time' Barrons.com
Dec-05-17 12:15PM  Biotech Stocks May See a New M&A Wave in 2018 Investopedia
12:10PM  Gilead Sciences, University of Houston and others launch $100M initiative to address HIV/AIDS crisis in South American City Business Journals
Dec-04-17 08:08AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
06:30AM  Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States Business Wire
Dec-03-17 09:09AM  5 Top Biotech Stocks to Buy Now Motley Fool
Dec-01-17 05:58PM  3 Drug/Biotech Stocks in Focus on World AIDS Day Zacks
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
06:00AM  Why Gilead's Highly Touted Stock Has No Upside Investopedia
Nov-30-17 05:16PM  Does Gilead's Kite Acquisition Offer A New Buying Opportunity? Investor's Business Daily
01:58PM  Maxim Explains Why Gilead Sciences Is A Now A Buy Benzinga
01:29PM  Gileads Cell Therapy Opportunity Tempts Maxim to Join the Bullish Camp SmarterAnalyst
01:13PM  Gilead Sciences Stock Upgraded: This Is the Power of Free Motley Fool
09:39AM  Gilead Stock Could Have 50% Upside Barrons.com
09:36AM  Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017 Capital Cube
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
07:30AM  Are Viruses a Problem for CAR-T Drugmakers? Motley Fool
Nov-29-17 01:20PM  There's little to stop the U.S. economic growth engine: NYSE trader Yahoo Finance Video
11:18AM  Trump's stock Tweets and the ECB's risk warnings are both correct Yahoo Finance Video
08:41AM  3 Dividend Stocks With Better Yields Than McDonald's Motley Fool
Nov-28-17 03:15PM  New Pharma ETF PILL : What Investors Need to Know Zacks
11:03AM  This is how Jay Powell might slip up in the Senate today and move the markets Yahoo Finance Video
07:30AM  Analysis: Positioning to Benefit within Garmin, J P Morgan Chase, Gilead Sciences, Windstream, Cardinal Health, and QEP Resources Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
01:39AM  Gilead (GILD) Down 7.9% Since Earnings Report: Can It Rebound? Zacks
Nov-27-17 05:59PM  "Fast Money" final trades: GILD, AMZN and more CNBC Videos
01:52PM  ETFs with exposure to Gilead Sciences, Inc. : November 27, 2017 Capital Cube
01:43PM  This market feels like Groundhog Day: NYSE trader Yahoo Finance Video
01:43PM  Smart money is planning for the end of this bull market: NYSE trader Yahoo Finance Video
12:05PM  Stocks are taking a turkey nap this week Yahoo Finance Video
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-24-17 02:11PM  J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space Zacks
01:06PM  CAR-T Therapy Space 2017 Progress Report Zacks
Nov-23-17 10:41AM  Can Gilead Sciences Incs (GILD) ROE Continue To Surpass The Industry Average? Simply Wall St.
08:04AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-22-17 10:42AM  Deere stock rips higher after upgrading 2018 forecast Yahoo Finance Video
10:29AM  Gilead: The Leader of the Packor Just Another Follower? Barrons.com
09:28AM  J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen Zacks
09:00AM  Gilead Sciences to Present at the Nasdaq 37th Investor Program on Wednesday, December 6 Business Wire
Nov-21-17 01:32PM  Today's surge in stocks kicks off the Santa Claus rally: NYSE trader Yahoo Finance Video
12:35PM  The 1 Thing Missing From Gilead Sciences' 2018 Priority List Motley Fool
11:26AM  This is what a Trump-stacked Federal Reserve will look like Yahoo Finance Video
11:26AM  Bitcoin barely bats an eye after $31 million cryptocurrency heist Yahoo Finance Video
10:31AM  How Mercks Zepatier and Isentress Are Positioned Market Realist
Nov-20-17 11:05AM  Here's what will be moving stocks this week Yahoo Finance Video
11:05AM  Bitcoin's next stop is $9,000or $7,000 Yahoo Finance Video
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-18-17 09:37AM  Better Buy: Biogen Inc. vs. Gilead Sciences Motley Fool
Nov-17-17 07:09AM  Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3 Zacks
Nov-16-17 05:43PM  Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms Investor's Business Daily
Nov-15-17 08:17PM  3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock Motley Fool
08:57AM  Trade of the Day: Gilead Sciences, Inc. (GILD) InvestorPlace
08:10AM  Todays Research Reports on Trending Tickers: Gilead Sciences and Geron Corporation ACCESSWIRE
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-14-17 03:03PM  7 Life Science Stocks to Buy Today InvestorPlace
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Nov-13-17 09:28PM  What Investors Need to Know About Investing in Low PE Stocks Motley Fool
05:18PM  Biotech ETFs: What Lies Ahead? Zacks
03:43PM  Gilead: Falling Sales+Higher Spending=Lower Profits Barrons.com
10:15AM  As Gilead's Outlook Dims, Argus Downgrades Benzinga
Nov-12-17 08:00AM  3 Top Biotech Stocks for 2018 Motley Fool
Nov-10-17 10:40AM  Short Sellers Grow More Selective on Major Biotechs 24/7 Wall St.
Nov-09-17 02:53PM  Biotech Celgene Could Rebound By More Than 15% Investopedia
08:53AM  You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018 Motley Fool
02:41AM  Edited Transcript of GILD earnings conference call or presentation 26-Oct-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 07:04PM  Cramer's lightning round: Step aside, Exxon. Cimarex's mo... CNBC Videos
01:14PM  6 Reasons Gilead Didn't Overpay for Kite Barrons.com
01:05PM  How Gilead Sciences Has Maintained Its Dividend Trajectory Market Realist
08:00AM  Today's Research Reports on Trending Tickers: Exact Sciences and Gilead Sciences ACCESSWIRE
Nov-06-17 03:25PM  Top 5 Biotech Stocks for 2017 Investopedia
03:04PM  Bluebird: Can It Keep Singing? Barrons.com
12:43PM  Glaxo vs Gilead: Put 'Em Up? Barrons.com
Nov-03-17 01:52PM  Nine years of outsized stimulus is finally taking hold in the US economy: NYSE trader Yahoo Finance Video
Nov-02-17 03:13PM  What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October? Motley Fool
02:49PM  Why Juno Therapeutics Shares Are Going Up 21.2% Today Motley Fool
10:38AM  GSK and Gilead go head to head as HIV drugs enter new phase Reuters
04:45AM  Sharp Drop Celgene Corporation Stock May Have Just Created an Entry Point InvestorPlace
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM